uBriGene targets North American growth with buy of Mustang facility

19 May 2023
mustang_bio_large

Canada-based cell and gene therapy contract development and manufacturing organization (CDMO) uBriGene is expanding into the US market with the acquisition of a state-of-the-art GMP manufacturing facility from US cell and gene therapy specialist Mustang Bio (Nasdaq: MBIO).

Financial terms of the deal were not disclosed, but Mustang’s shares were down 2.6% at $4.10 by mid-morning.

The CDMO has an established global footprint with two GMP manufacturing facilities in China and its headquarters in Vancouver, Canada. The latest move will see uBriGene expand its global headcount to over 500 employees.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology